Company news
Propanc Biopharma, Inc. (NASDAQ:PPCB) news
Propanc Biopharma, Inc. news releases on 6ix. Latest, Dec 18, 2023: Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment…
Press releases — page 2
Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities
December 17, 2023
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
December 12, 2023
Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells
November 6, 2023
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia
August 14, 2023
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
July 12, 2023
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
July 4, 2023
Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America
May 22, 2023
Propanc Biopharma Announces Reverse Stock Split
May 21, 2023
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer
March 27, 2023
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
March 15, 2023
Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén
December 14, 2022
Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer
November 29, 2022
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer
November 14, 2022
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
October 25, 2022
Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027
September 28, 2022
Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment
September 7, 2022
Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office
August 15, 2022
Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada
August 2, 2022
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade
July 27, 2022
Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients
July 11, 2022
Propanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions
July 4, 2022
Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split
June 23, 2022
Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer
June 21, 2022
Propanc Biopharma’s PRP to Target 80 – 90% of Cancer Cases
June 13, 2022
Propanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives Significantly
May 31, 2022
Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer
May 25, 2022
Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use
May 17, 2022
Propanc Biopharma Offers a Novel Way to Stop Cancer
May 10, 2022
Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in Preparation for Phase I First-In-Human Study
May 1, 2022
Propanc Biopharma’s Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment
April 12, 2022
Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care During Global Pandemic
April 5, 2022
Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent & Trademark Office
March 21, 2022
Propanc Biopharma’s CEO Believes Proenzyme Therapy May Become the Healthcare Solution of Choice for Treating Cancerous Solid Tumors
March 15, 2022
Propanc Biopharma’s Cancer Stem Cell Technology Offers Renewed Hope to Achieve a Total Victory Against Metastatic Cancer
March 1, 2022
Propanc Biopharma’s Joint Research Partnership with the Universities of Jaén and Granada Enters 13th Year
February 22, 2022
Propanc Biopharma Demonstrates Significant Effects of Proenzyme Therapy on the Tumor Microenvironment
December 20, 2021
Propanc Biopharma Enters into $5 Million Equity Purchase Facility with Dutchess Capital Growth Fund LP
December 13, 2021
Propanc Biopharma Appoints Paul Patrizio as Strategic Advisor to Establish US Based R&D Operating Subsidiary, Cellmed Bio LLC, in New Jersey
November 2, 2021
Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Tumor Potential of Proenzymes
May 16, 2021
Propanc Biopharma Provides Upcoming Milestones
March 24, 2021
Propanc Biopharma Provides A Shareholder Update for 2021
March 2, 2021
Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients
February 14, 2021
Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment
January 27, 2021
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
January 17, 2021
Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers
January 10, 2021
Propanc Biopharma Receives First Granted Patent for Method to Treat Cancer Stem Cells from Australian Patent Office
December 20, 2020
Propanc Biopharma Receives Investment from Institutional Investor
July 27, 2020
How Propanc Biopharma Is Joining the Fight with Cancer Patients Who Are Increasingly Vulnerable to the COVID-19 Global Pandemic
April 15, 2020
Propanc Biopharma Receives First Allowance for Key Patent Family from Australian Patent Office
April 13, 2020
Propanc Biopharma Enters Into a $3 Million Financing with Institutional Investor
March 30, 2020